Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Carocare Wellness vs JRNYS

Carocare Wellness
Graded #378

Lower grade

vs+4.399999999999999
JRNYS
Graded #267

Higher grade

The verdict

JRNYS takes it — 62.5/100 to 58.1/100.

JRNYS grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. JRNYS is a telehealth weight-loss membership built around branded GLP-1 medications, and the membership itself buys no medication.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCarocare Wellness +14
59
45
Dose & formulationCarocare Wellness +6
64
58
Clinical oversightJRNYS +15
69
84
Labs & monitoringJRNYS +18
53
71
FulfillmentJRNYS +5
60
65
Contract termsJRNYS +35
20
55
Carocare Wellness · left barJRNYS · right bar

The numbers

MetricCarocare WellnessJRNYS
WeighScore58.1/10062.5/100
GradeCC
Scorecard rank#378#267
Semaglutide$170/mo (compounded)Not disclosed
Tirzepatide$200/mo (compounded)Not disclosed
Coverage1 stateCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Carocare Wellness

Graded #378 · C

Strengths

  • Real, named local clinic in Houston with hands-on provider support, in-person visits and Google-reviewed patient experiences
  • Low entry pricing — semaglutide from $170 and tirzepatide from $200 in month 1, with 3-month bundles ($500 / $600) that cut the effective monthly cost
  • Packages include ongoing provider support, supplies and delivery
  • Also offers IV hydration and NAD+ if you want broader wellness services in one place

Where it loses points

  • Houston/Texas only — no nationwide telehealth, so it is not an option outside the local area
  • Dose-escalating pricing climbs steeply (semaglutide reaches $330 by month 5; tirzepatide $425 by month 6)
  • Compounding pharmacy is not named, and there is no LegitScript or published clinical-oversight detail
  • Small single-location operation with no patient portal — booking and support run through Calendly and direct contact
  • Compounded semaglutide and tirzepatide only — no brand-name or oral options
JRNYS

Graded #267 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

Where it loses points

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard